Macrogenics (MGNX) Accumulated Expenses (2012 - 2026)

Macrogenics (MGNX) has reported Accumulated Expenses for 15 consecutive years, with $18.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 33.74% year-over-year to $18.4 million; the TTM figure through Mar 2026 stood at $18.4 million (down 33.74% YoY), while the FY2025 annual figure was $22.2 million, down 24.22% from the prior year.
• Accumulated Expenses eased to $18.4 million in Q1 2026 per MGNX's latest filing, from $22.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $33.3 million in Q3 2022 and bottomed at $18.1 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $26.0 million across 5 years, with a median of $25.5 million in 2023.
• Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 35.62% — and 2025, when it surged 53.39%.
• Macrogenics' Accumulated Expenses stood at $29.0 million in 2022, then dropped by 16.41% to $24.2 million in 2023, then advanced by 21.02% to $29.3 million in 2024, then fell by 24.22% to $22.2 million in 2025, then fell by 17.02% to $18.4 million in 2026.
• Business Quant data shows MGNX's Accumulated Expenses at $18.4 million in Q1 2026, $22.2 million in Q4 2025, and $23.1 million in Q3 2025.